



AgiOS Pharmaceuticals to Present New Clinical Data from AG-221 Ongoing Phase 1 Study at the 19th Congress of the European Hematology Association

May 22, 2014

- Company to Host Conference Call and Webcast on Monday, June 16, 2014 -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2014-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that new clinical data from the Phase 1 study of AG-221, an orally available, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association (EHA) taking place June 12 -15, 2014 in Milan, Italy.

"We look forward to sharing these new clinical data with the medical community during the late-breaker session at EHA," said David Schenkein, M.D., chief executive officer of Agios. "The data build upon the AG-221 preliminary results we presented last month at the American Association for Cancer Research (AACR) Annual Meeting, and include additional patients from existing and new dose cohorts."

Title: A Phase I Study of AG-221, a First in Class, Potent Inhibitor of the IDH2-Mutant Protein, in Patients with IDH2 Mutant Positive Advanced Hematologic Malignancies

Presentation time: Saturday, June 14 at 1:30 p.m. CEST

Session title: Late breaking 1

Presenter: Stephane De Botton, M.D., Institut de Cancerologie Gustave Roussy, Villejuif, France

Abstract code: LB2434

Conference Call Information

Agios will host a conference call and webcast on Monday, June 16, 2014, at 8:30 a.m. EDT to review the clinical data presented at EHA from the ongoing Phase 1 study of AG-221. To participate in the conference call, please dial 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 49387254. A replay of the call will be available approximately two hours after the conclusion of the call and will be accessible through June 23, 2014. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and provide the access code 49387254. The webcast can be accessed live or in archived form under "Events & Presentations" in the Investors and Media section of the company's website at www.agios.com.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the benefit of its strategic plans and focus. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios' current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios' product candidates will successfully continue. There can be no guarantee that any positive developments in Agios' business will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other important factors, including: Agios' results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; Agios' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Agios' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; Agios' ability to maintain key collaborations, such as its agreement with Celgene; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in Agios' Quarterly Report on Form 10-Q for the quarter ended March 31, 2014, and other filings that Agios may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Agios expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Agios Pharmaceuticals, Inc.
Lora Pike, 617-649-8608
lora.pike@agios.com